PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy

Neurology

Volumn 82, Issue 23, 2014, Pages 2085-2091

  Nelson, Michael D ^a   Rader, Florian ^a   Tang, Xiu ^a   Tavyev, Jane ^a   Nelson, Stanley F ^b,c   Miceli, M Carrie ^c   Elashoff, Robert M ^d,e   Sweeney, H Lee ^f   Victor, Ronald G ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Departments of Human Genetics   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Departments of and Pathology Laboratory Medicine David Geffen School of Medicine at UCLA ^*  (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFLAZACORT; LISINOPRIL; LOSARTAN; PHOSPHODIESTERASE V; PREDNISONE; SILDENAFIL; TADALAFIL;

ADOLESCENT; ARTERY BLOOD FLOW; ARTICLE; ATTENUATION; BRACHIAL ARTERY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DOPPLER ECHOGRAPHY; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DUCHENNE MUSCULAR DYSTROPHY; DYNAMOMETER; ENZYME INHIBITION; EXERCISE; FLUSHING; FOREARM; HAND GRIP; HUMAN; HYPEREMIA; LOW DRUG DOSE; MALE; MUSCLE BLOOD FLOW; MUSCLE ISCHEMIA; NEAR INFRARED SPECTROSCOPY; OPEN STUDY; ORTHOSTATIC STRESS; OXYGENATION; PATIENT MONITOR; PENIS ERECTION; PRIORITY JOURNAL; REAL TIME ULTRASOUND SCANNER; REFLEX; RESTING HEART RATE; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SKELETAL MUSCLE; SYMPATHETIC REFLEX; TRANSDUCER; VASOCONSTRICTION;

ADOLESCENT; CARBOLINES; CHILD; EXERCISE; FOREARM; HUMANS; ISCHEMIA; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SPECTROSCOPY, NEAR-INFRARED; SULFONES; SYMPATHETIC NERVOUS SYSTEM; VASOCONSTRICTION;

EID: 84903973539     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000498     Document Type: Article

References (27)

1. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy: part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9: 77-93.
2. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy: part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9: 177-189.
3. Moxley R, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64: 13-20.
4. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320: 1592-1597.
5. Kobayashi YM, Rader EP, Crawford RW, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 2008;456: 511-515.
6. Asai A, Sahani N, Kaneki M, Ouchi Y, Martyn JAJ, Yasuhara SE. Primary role of functional ischemia, quantitative evidence for the two-Hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS One 2007;2: e806.
7. Lai Y, Thomas GD, Yue Y, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 2009;119: 624-635.
8. Thomas GD, Ye J, De Nardi C, Monopoli A, Ongini E, Victor RG. Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy. PLoS One 2012;7: e49350.
9. Adamo CM, Dai DF, Percival JM, et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2010;107: 19079-19083.
10. Khairallah M, Khairallah RJ, Young ME, et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci U S A 2008;105: 7028-7033.
11. Percival JM, Whitehead NP, Adams ME, Adamo CM, Beavo JA, Froehner SC. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J Pathol 2012;228: 77-87.
12. Kawahara G, Karpf JA, Myers JA, Alexander MS, Guyon JR, Kunkel LM. Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2011;108: 5331-5336.
13. Bischoff E. Potency, selectivity, consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004;16: S11-S14.
14. Martin EA, Barresi R, Byrne BJ, et al. Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med 2012;4: 162ra155.
15. Herr MD, Hogeman CS, Koch DW, Krishnan A, Momen A, Leuenberger UA. A real-Time device for converting Doppler ultrasound audio signals into fluid flow velocity. Am J Physiol Heart Circ Physiol 2010;298: H1626-H1632.
16. Hansen J, Thomas GD, Harris SA, Parsons WJ, Victor RG. Differential sympathetic neural control of oxygenation in resting and exercising human skeletal muscle. J Clin Invest 1996; 98: 584-596.
17. Victor RG, Seals DR, Mark AL. Differential control of heart rate and sympathetic nerve activity during dynamic exercise: insight from intraneural recordings in humans. J Clin Invest 1987;79: 508-516.
18. Duboc D, Meune C, Pierre B, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007;154: 596-602.
19. Sander M, Chavoshan B, Harris SA, et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2000;97: 13818-13823.
20. Duboc D,Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45: 855-857.
21. Ramaciotti C, Heistein LC, Coursey M, et al. Left ventricular function and response to enalapril in patients with Duchenne muscular dystrophy during the second decade of life. Am J Cardiol 2006;98: 825-827.
22. Thomas GD, Zhang W, Victor RG. Impaired modulation of sympathetic vasoconstriction in contracting skeletal muscle of rats with chronic myocardial infarctions: role of oxidative stress. Circ Res 2001;88: 816-823.
23. Gao L, Wang W, Li YL, et al. Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase. Circ Res 2004;95: 937-944.
24. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2006;21: 20-27.
25. Vongpatanasin W, Wang Z, Arbique D, et al. Functional sympatholysis is impaired in hypertensive humans. J Physiol 2011;589: 1209-1220.
26. Zhao W, Swanson SA, Ye J, et al. Reactive oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin II-dependent hypertension. Hypertension 2006;48: 637-643.
27. Takatsuki S, Calderbank M, Ivy D. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 2012;33: 683-688.